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“Mankind’s enemy is ignorance; the enemy of ignorance is education.” 
“Science is the most reliable guide in life.” 
-Mustafa Kemal ATATÜRK
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CHAPTER 1: SUMMARY 
 
In the past years, nanoparticle usage and research increased enormously in different 
fields, especially in the clinical sciences for drug delivery and imaging. Selection of 
the most suitable type of nanoparticle is not always easy because of a broad material 
variety and different physicochemical characteristics. Depending on the purpose, the 
safe usage of nanoparticles in vivo needs to be ensured first to predict and eliminate 
unwanted effects like agglomeration, loss of function, immune system responses (i.e. 
inflammation), or toxicity after intravenous application. To guarantee the safe usage 
of nanoparticles, there are various hazard evaluation strategies for different scenarios 
for example for nanomedicines. Drug delivery with nanomedicines has advantages 
like increased absorbability, increased in vivo half-life, and decreased drug dosage 
needs to reach the same therapeutic effect. Amongst others, superparamagnetic iron 
oxide nanoparticles (SPIONs) and liposomes are already used as medicinal 
nanoparticles and are approved from the US Food and Drug Administration (FDA). 
Examples are Feraheme®, which is a ferumoxytol injection for iron deficiency 
treatments and Doxil®, a liposomal doxorubicin hydrochloride chemotherapy drug. 
SPIONs are also used as contrast agents because of their high-dense core and the 
possibility to synthesize very small diameters below 10 nm, which can even penetrate 
into smallest fenestrations of i.e. the kidneys. This work is divided into two main parts: 
Part one was the analysis of different nanoparticle safety evaluation strategies to 
propose a new hazard evaluation guideline for intravenously applied nanoparticles. 
This was part of the NanoREG II European Union’s Horizon 2020 research and 
innovation program under grant agreement 646221.  
 




Part two started with the synthesis and physicochemical characterization of hybrid 
nanoparticles made out of SPION cores and liposome coatings. The coatings were 
differently modified with additions like polyethyleneglycol for increased in vivo half-life 
or folic acid for renal targeting.  Injected into zebrafish (Danio rerio) embryos, their 
biodistribution and toxicity was analyzed. Various methods like confocal laser 
scanning microscopy and synchrotron X-ray radiation micro-computed phase-
contrast tomography were used and compared with each other. Finally, those hybrid 
nanoparticles were manipulated in vivo with external magnets to increase phagocytic 
uptake and also with electromagnetic fields and acoustic waves for controlling the 
nanoparticles in vivo in terms of agglomeration and rotation. 
 
| 3   
 
CHAPTER 2: INTRODUCTION 
 
I. NANOMATERIALS 
The history of nanoscience started in the 19th century with Michael Faraday1. He was 
investigating the optical properties of gold and silver colloids and found out in 1857, 
that there is a size-dependent color change of “colloidal ruby gold”. The particle 
solutions were changing their color depending on their size or shell thickness. This 
phenomenon was already used since the 4th century by Romans to make dichroic 
glass2. It continued in the 9th century with lustre pottery, ceramic glazes containing  
copper, silver and other nanoparticles firstly used by the Islamic world in 
Mesopotamia3. Also European cathedrals made use of vibrant stained glass windows 
in the 10th century, containing gold chloride and other metal oxides and chlorides for 
coloring4. 
The breakthrough in visualization of those nanoparticles was the invention of the first 
transmission electron microscope in 19315. With this development, it was possible to 
magnify structures up to one million times compared to up to 2000 times with a light 
microscope and herewith the possibility to see nanostructures and even atoms was 
given6.   
 
DESCRIPTION OF NANOMATERIALS 
Nanoparticles are not only man-made but did exist in nature already (Figure 1)7. As 
a first group, natural nanoparticles consist of different materials such as small 
molecular breakdown products (i.e. humic matter), organic compounds and 
(oxyhydr)oxides generated during the chemical and physical decomposition of rocks 
containing iron (Fe), manganese (Mn) and aluminum (Al) and aluminosilicates8. Also 
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dust storms9, volcanic eruptions10, forest fires11, and ocean water evaporation12 are 
generating enormous amounts of naturally occurring nanoparticles like carbon black 
and salt aerosols13. The second group are the engineered nanoparticles. A lot is 
produced during the daily live by transportation (diesel and engine exhaust)14, 
industrial operations, and charcoal burning. Also cigarette smoke15 and building 
demolition16 can lead to nanoparticle production like carbon nanotubes (CNTs), lead, 
glass, and respirable asbestos fibers13. Biomedical and healthcare products also 
contain synthetic nanoparticles made of titanium dioxide in sunscreens17 or silver 
nanoparticles in deodorants and food storage containers18. As a third group, 
nanostructures are also present as biological organisms like viruses, nanobacteria, 
algae, fungi, yeast, and bacterial spores13.  
 
 
Figure 1 - Overview of nanomaterials and their cycle. Production is either naturally 
or man-made and is reversible between the groups of earth components, 
precursors, and nanomaterial examples (changed from19). 
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DEFINITION OF NANOPARTICLES (SUMMARIZED FROM THE ISO DEFINITION20) 
Nano-objects are defined by the International Organization of Standardization (ISO) 
as “objects with one or more external dimensions in the nanoscale, (…) which covers 
a length range approximately from 1 nm to 100 nm”. Those nano-objects are divided 
into three main groups, the nanoparticles (3 external dimensions in the nanoscale), 
nanofibers (2 external dimensions in the nanoscale), and nanoplates (1 external 
dimension in the nanoscale). Also, the term “primary-particle” is used to define the 
original source particle which can build agglomerates (“collection of weakly or 
medium strongly bound particles where the resulting external surface area is similar 
to the sum of the surface areas of the individual components”) or aggregates (“particle 
comprising strongly bonded or fused particles where the resulting external surface 
area is significantly smaller than the sum of surface areas of the individual 
components”).  
 
TYPES OF NANOPARTICLES 
Depending on their size, shape, material, and physicochemical properties, 
nanoparticles are classified into different groups. Those are carbon-based 
nanoparticles including fullerenes and carbon nanotubes, metal nanoparticles made 
out of alkali or noble metals like rubidium oxide or gold, ceramics nanoparticles which 
are non-metallic and inorganic, semiconductor nanoparticles with metallic and non-
metallic characteristics at the same time, organic and capsule- or sphere-shaped 
polymeric nanoparticles, spherical lipid-based nanoparticles with a typical size range 
between 10 to 100 nm, quantum dots made out of nanocrystals of semiconducting 
materials, and nanocarriers which can be used as e.g. drug carriers. Also, all types 
of hybrids of those nanoparticles exist21–23. In this work, we will focus on nanoparticles 
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used in clinical sciences, especially SPIONs, liposomes, and their hybrid 
nanoparticles for drug delivery, targeting and imaging. 
 
METAL NANOPARTICLES 
Metal nanoparticles consist of a dense metal core and are typically spherical. They 
can be made of alkali or noble metal(oxide)s. One example are SPIONs with a broad 
application field and are produced by e.g. liquid phase methods or thermal 
decomposition, both of them allowing precise size control and result in narrow size 
distributions24,25. One of the first and easiest methods to produce iron oxide 
nanoparticles is the co-precipitation. It is the reduction of iron 2+ and 3+ oxide salts in 
an alkaline environment with help of stabilizing agents like citric acid, which was 
already described in the 80s26,27. These SPIONs can then be further modified i.e. by 
coating them with oleic acid to introduce hydrophobic characteristics for further usage 
in organic solvents like ethanol or chloroform28. In medicine, they are interesting 
because of their properties such as superparamagnetism and high field irreversibility, 
that allows to agglomerate the SPIONs in specific regions by an external magnetic 
field i.e. for targeting. After the field is removed, the SPIONs no longer show magnetic 
behavior29. The combination of external magnetic fields and magnetic drug delivery 
agents was first mentioned in the 1970s by Freeman et al.30. Since then, they are 
also used as contrast agents for visualization of labelled cells by magnetic resonance 
imaging (MRI)31, targeting and contrast enhancement of breast cancer32, and 
simultaneous imaging and chemotherapy (theranostics)33. They can also be used 
medicinal i.e. as SPIONs capped with vitamin C for oral treatment of iron deficiency 
anemia to increase the hemoglobin concentration effectively34 or for intravenous 
anemia treatment of chronic kidney disease (CKD) with ferumoxytol (Table 1)35–37.  
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Table 1 – Clinically approved SPIONs by the US Food and Drug Administration (FDA) with names, material 




Lipid nanoparticles have the advantage to be the least toxic of all nanoparticles in 
vivo and are used for DNA/RNA or drug delivery by encapsulation39. Field of 
applications are i.e. immunotherapy in cancer treatment for antitumor immune 
response40, neurological disorders like Parkinson’s disease (PD) or multiple sclerosis 
(MS)41, or even for non-invasive brain targeting by by-passing the blood-brain barrier 
(BBB)(Table 2)42. One of the first liposome-encapsulated drug formulations 
containing Doxorubicin was already mentioned in the 80s for cancer treatment with 
lesser side effects than the administered free drug which is also known as Adriamycin 
due to the discovery at the Adriatic Sea43,44. It was the first clinically approved drug 
by the US Food and Drug Administration (FDA) named Doxil® in 199545. Advantages 
of liposome-encapsulated Doxorubicin are i.e. increased half-life in blood circulation, 
protection from the reticuloendothelial system (RES) by pegylation, higher loading 
capacities, and passive targeting of the tumors by the enhanced permeability and 
retention (EPR) effect45. Liposomes are drug-loaded by transmembrane gradients, 
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so called remote loading, which enabled production of liposomal formulations like 
Doxil®. It enables the possibility to have enough liposomal drug-loads for therapeutic 
effects46. Liposomes with a typical average size of 100 nm contain an aqueous core 
and an outer lipid shell consisting of phospholipids, ideal for hydrophilic drug loading 
with i.e. paclitaxel, cisplatin or doxorubicin while hydrophobic drugs are entrapped in 
the outer lipid bilayer shell47.  Synthesis of liposomes can be done with different 
techniques like the microfluidic hydrodynamic focusing (MHF) approach, in which the 
lipids and hydrophobic substances are dissolved in an organic solvent (i.e. alcohol) 
and the hydrophilic substances in water or phosphate-buffered saline (PBS)48. In a 
Y-shaped mixing chamber (i.e. with the automated mixing platform  
NanoAssemblr™), those two phases are mixed together and because of the “self-
assembly”, liposomes are formed49. During this process, the size, polydispersity index 
(PDI) and transfection efficiency of the liposomes can be reproducibly controlled with 
the total flow rate (TFR) and the flow rate ratio (FRR) between the two phases49,50.  
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COMBINATION OF METAL AND LIPID NANOPARTICLES (HYBRID NANOPARTICLES) 
For increasing application possibilities and combining multiple properties, different 
types of nanoparticles can be combined to so called “hybrid nanoparticles” (Figure 
2)52. One example is a combination between metal dense-core nanoparticles (i.e. 
SPIONs) within a phospholipid outer shell/coating (liposomes). They are able to 
transport hydrophilic or hydrophobic drugs and have at the same time the possibility 
to be magnetically manipulated i.e. for targeting or imaging in vivo53–55. It is possible 
to induce hyperthermia at the target location by an alternating current (AC) magnetic 
field (AMF) to locally destroy tumors or for heat induced drug release56–58. One 
example of such hybrid nanoparticles are pegylated SPIONs with incorporated 
Doxorubicin in the polymeric shell which were effective in detecting Lewis lung 
carcinoma and delivering efficient amounts of the drug to the target for successful 
applied theranostics59.  
 
 
Figure 2 – Example of a hybrid nanoparticle with an inorganic core (SPION) and a lipid 
coating with various possible modifications. Lipophilic and hydrophilic drugs can be 
loaded, liposomes can be modified to be pH- or temperature sensitive, pegylated for 
shielding, and targeting agents can be added (changed from60) 
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NANOPARTICLE SAFETY AND GUIDELINES 
Various information and guidelines are existing to guarantee the safety of 
nanoparticles for medicinal usage for therapeutic, diagnostic or theranostic 
purposes61. Especially their different behavior compared to corresponding bulk 
materials makes it impossible to treat and regulate them the same way62–64. Talking 
about a general safety for all nanoparticles is difficult because of their broad 
application field with many different types65. But nevertheless, the topic is discussed 
in many publications and guidelines, even in the European Union nanoparticle 
regulatory approach called NanoREG66–72. This chapter will focus on intravenously 
(IV) applied nanoparticles used in clinical sciences. A lot of nanoparticles for 
medicinal usage are liposome-based with more than 12 already in the market and 
more than 20 still in the clinical phase (Table 2)73. One of the major problems is the 
long-term storage of these drugs because of physicochemical destabilization in 
aqueous solutions. The preferred method therefore is the lyophilization which 
ensures the long-term stability compared to other methods74. Also, more and more 
SPIONs are used for drug delivery, imaging and theranostics (Table 1)38. After IV 
injection, the nanoparticles immediately interact with the biological environment75. A 
biological coating of biomolecules, which are present in the blood plasma, will form 
around the particles, the so-called protein corona76. This can affect the nanoparticle 
behavior in vivo77. Therefore it is essential to characterize the nanoparticles 
additionally in a solution containing 10 % fetal bovine serum78. This will ensure, that 
the drug release, biodistribution, toxicity, intracellular uptake, immunological 
response, and in vivo targeting will not change after IV administration76. Further 
information and proposed techniques to ensure the safety of IV administered 
nanoparticles is explained by the following pages based on the review from Cörek et 
al.79: 
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Nanotoxicology is a very complex topic without defined standard testing protocols 
which are accepted from regulatory authorities. To solve this problem, more and more 
testing strategies were proposed in the last years to improve the time and money 
consuming case-by-case evaluations. These strategies are mainly focused on 
inhalation or oral administration but not on IV administration on purpose. Therefore, 
ensuring the safe usage of those nanoparticles is essential, especially to fill the 
existing gap in terms of nano-specific regulation and safety assessment for medical 
candidates. The term nanosafety is an interaction between the biological system, 
surface properties, and physicochemical properties of the nanoparticles. This hazard 
evaluation strategy for nanomedicines (HES) is an approach with three tiers (Figure 
3). Based on the physicochemical properties (tier 1) and nanoparticle interactions (tier 
2), the hazard assessment (tier 3) can be created. This helps at the end in the 
decision and prediction process.  
 
 
Figure 3 - Proposed hazard evaluation strategy from Cörek et al.79 with different 
tiers to characterize and group nanoparticles in different hazard groups 
depending on their characteristics. Depending on the outcomes, those 
nanoparticles are declared as safe to use as IV applications. 
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To ensure the international availability, standardized testing protocols from the 
European Nanomedicine Characterization Laboratory (EUNCL) are used. The first 
tier serves as a starting point before continuing with in vitro toxicity testings to collect 
information like the zeta potential, aqueous stability, shape, size, contamination, and 
size distribution. This step-by-step approach shows, if the candidate is qualified to 
continue as an injectable nanoparticle to tier 2 or fails because of i.e. contamination 
that cannot be cleared by purification. 
To find out the interactions of injectable nanoparticles in tier 2, cellular uptake and 
intracellular persistence is measured and based on the results, the particles are 
grouped in four different categories. Ideally, the cellular uptake is determined by 
combining qualitative and quantitative methods like confocal laser scanning 
microscopy (CLSM) together with flow cytometry. The administered dose and the 
incubation times are important values which should be considered. The 
corresponding cell types are chosen based on first contact after injection which are 
likely to be endothelial cells. The persistence is determined with the same cell types 
by looking on the intracellular degradation level after defined periods of time, i.e. by 
electron microscopy.  
After categorizing the nanoparticles, further testings are done in tier 3 based on the 
respective category. Those are set up with eight different assays (complement 
activation, platelet aggregation, hemolysis, oxidative stress, cell viability, 
phagocytosis, inflammation, and DNA damage) with increasing amounts from 
category one to four because of possible increasing interaction chains in vivo with 
increasing uptake and persistence (Figure 4). Nevertheless, those categories don’t 
necessarily define the toxicity. But the possibility of more/longer interactions also 
increases the risk, which needs to be determined and evaluated. 
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Figure 4 – Tier 3 of the HES approach with different hazard 
assessment tests based on the four categories the 
nanoparticles entered after tier 2. The categories are 
defined by high/low intracellular persistence and cellular 
uptake of the nanoparticles (copied from79).    
 
At the end of the day, this approach is an example of a concept which is easy and 
robust to apply, reduces costs, and is completely application-oriented. It fastens up 
and standardizes preclinical safety evaluations, reduces in vitro testings by pre-
selecting relevant candidates, promotes the 3R principles, identifies off-target effects 
in vivo, and finally helps grouping of nanoparticles. This will help researchers and 
developers during product design and will lead a step further to much needed 
standardized safety testing strategies for the future.  
 
II. ZEBRAFISH (DANIO RERIO) 
First scientific recordings of Danio rerio were made in 1822 from the naturalist Francis 
Hamilton. He described them as beautiful but not from value80. Danio rerio live in 
South Asia in India, Pakistan, Nepal up to the Southern Himalayas in the North81. 
Found in fresh water i.e. rivers, channels, and small streams, they can survive in a 
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broad temperature and pH-range affecting their mutations and breeding time82.  
Inbred zebrafish can live in average 3.5 years, with oldest individuals living up to 5.5 
years83. Today it is known, that zebrafish have together with humans and mouse the 
best genome sequence assembly and gene annotation of all vertebrates with almost 
70 % orthologues with human genes84,85. Danio rerio belongs to the class of 
Actinopterygii and their subclass Teleostei which are part of the Cyprinidae family86. 
This Danio genus contains more than 40 different fish together with Danio rerio as an 
important vertebrate model for biomedical research87.  
 
ANATOMY AND HISTOLOGY 
Danio rerio have many anatomical and physiological properties in common with 
vertebrates including humans88. Their maximal length is up to 40 mm and they have 
a “fusiform and laterally compressed body shape with a terminal oblique mouth 
directed upwards”81. They express different types of dark blue lateral stripes, a typical 
phenotypic trait of this genus89. Three types of pigment cells are included in their color 
pattern, dark blue melanophores, gold xanthophores and iridescent iridophores90. 
There are various genetically modified strains with different phenotypes and 
characteristics such as the so called “casper”, a strain where the zebrafish are 
completely transparent because of a melanocyte and iridophore lack91. Compared to 
mammals, zebrafish have no medullary cavity so the hematopoiesis takes place in 
the interstitium of their kidneys92. Sinuses are lined with endothelial cells which are 
filtering the blood and adding new blood cells into the circulation93. The blood consists 
of erythrocytes for oxygen transport and thrombocytes for blood clotting94. 
Leukocytes play an important role for the immune system, which are consisting of 
neutrophilic and eosinophilic granulocytes95. Neutrophils are similar to the 
mammalian neutrophils but eosinophils differ and the question if they have a similar 
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function is not clear96. Around five to 15 % of the leukocytes are consisting of 
monocytes which are similar to mammalian monocytes and will develop into 
macrophages mainly in the kidney and spleen region of adult zebrafish97. The spleen 
and kidneys of zebrafish are the main filtering organs because like other teleosts, 
they don’t have lymph nodes98. Kidneys are quite similar to humans with nephrons 
consisting of glomerulus, proximal tubules, distal tubules, and collecting ducts92. The 
liver is the major player in metabolic homeostasis similar to mammals94. Also the 
brain is comparable to mammals and consists of five regions (telencephalon, 
diencephalons, mesencephalon, metencephalon, and myelencephalon)99. Another 
organ which is identical to higher vertebrates are the eyes consisting of three layers 
(tunica fibrosa, tunica vasculosa, and the retina)92. Very important for orientation, 
perception of sound, acceleration, and change in equilibrium are the otholiths. They 
are made of calcified stones and lie on sensory epithelium cells92.  In general, the 
zebrafish is a well-fit model organism to study human disease, toxicology and drug 
delivery because of the anatomical, developmental and histological similarities100.   
 
BREEDING AND DEVELOPMENT 
Zebrafish are regulated after the EU Directive 2010/63/EU that defines the protection 
of animals and is one of the most strict international standards for animal welfare and 
ethics101. In there, the earliest animal life-stages are not defined as protected and 
therefore, the zebrafish embryos are not considered as animals until 120 hours post 
fertilization at 28.5° C due to “depending feeding” from their yolk102. The following 
information about breeding are gathered from103 and say that as soon as new adult 
zebrafish arrive in the laboratories, they need to be hold in quarantine to eliminate 
the risks of pathogens and increase biosecurity. They are hold in commercially 
available glass or PVC tanks “fully integrated with filter systems, germicidal irradiation 
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(UVC) and light and temperature control units”. Their volume is around 10 liters and 
they are connected to a pure freshwater circulation system, where the used water is 
constantly purified and reused. The temperature is usually kept constant between 24 
and 29° C at a “static dark–light (D–L) cycle” of 10 hours dark and 14 hours light. The 
adult fish can be kept between 3-12 fish/L without the need to physically enrich the 
environment because of lack of evidence that it increases benefits. Feeding takes 
place 2-3 times a day with different living organisms like Artemia nauplii from a 
pathogen-free source. Zebrafish have a high fecundity with a female fish spawning 
hundreds of eggs per mating. It is recommended to keep two to three males together 
with six to seven females during mating process in smaller tanks overnight with a 
sieve and physical structures like plastic plants and small stones which are mimicking 
the natural environment. The morning after mating, the eggs are removed and 
cleaned from feces and hold constantly in embryo medium containing 0.5 mg/l 
methylene blue to reduce fungal infections in D-L cycle at 28.5 ± 0.5° C. Stocking 
density is 100 embryos in 35 ml of medium in a nine cm diameter Petri dish. Between 
matings, the used embryos should at least get a break of one week to allow recovery. 
After the eggs are hatched, the embryos immediately start to develop. Following 
information gathered from Kimmel et al. shows the different developmental stages104: 
After the fertilization, the zygote period (1-cell) starts where a first cleavage occurs. 
This continues with the cleavage period (2-cell), where every 15 minutes the cells 
divide themselves followed by the blastula period (128-cell). Followed by the gastrula 
(50%-epiboly), segmentation (3- and 14-somite), and pharyngula (prim-6) period, 
where the eggs are usually bleached to inhibit pigmentation with phenylthiourea 
(PTU), inhibiting TYR-dependent melanogenesis pathway, at a concentration of 75 
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µM105. After 48 hpf the hatching (long pec and protruding mouth) period is reached 
where the protruding-mouth is visible after 72 hpf (Figure 5).  
 
 
Figure 5 – Sketches made with a camera lucida of the zebrafish embryo at selected stages 
between 1-cell state at 0.2 hpf and fully developed embryo with a protruding mouth at 72 
hpf (changed from104) 
 
ZEBRAFISH AS A MODEL ORGANISM 
The first mentioning of zebrafish embryos as a model organism in laboratory research 
was in the early 1900s with a protocol for zebrafish handling106. In the following years 
between 1940s and 60s, several scientists used zebrafish for examination of 
developmental and behavioral biology, neurobiology, toxicology, and oncology. 
Starting from there, in the recent 40 years, zebrafish become a popular and well 
suited model organism in laboratories because of their easy handling and 
manipulation, high fecundity, rapid development, and small size86 (Figure 6). One of 
the key figures in adapting zebrafish to a broad range of people was George 
Streisinger, a molecular biologist and aquarium hobbyist, who understood the 
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advantages of the model organism and optimized their breeding and care, developed 
mutation, genetical and clonal analysis of cell origins tools and started also a first 
genetical screening of zebrafish107–109. His work was continued by his colleague 
Charles Kimmel, which is now one of the most cited scientists in the field of 
zebrafish110. In 1996, the categorization and descriptions of 1163 mutant zebrafish 
lines was published which set the genetical basis for the phenotypes111 and was 
completed by the zebrafish genome sequencing and comparison to human genome 
between 2001 and 201384.   
 
 
Figure 6 – Increase of publications including the words zebrafish, 
Brachydanio rerio, or Danio rerio in the last 30 years (copied from86) 
 
It was found out, that the genome of zebrafish contains around 26,000 genes over 
1.4 billion base pairs on 25 pairs of chromosomes. Today, there is a wide variety of 
transgenic zebrafish strains which express fluorescent proteins, Cre‐recombinases, 
cell‐death proteins, also with the ability to manipulate other proteins112,113. One of the 
zebrafish strains used in this work was the mpeg1:kaede strain expressing green 
fluorescent kaede protein in macrophages114. Also, zebrafish are used for 
toxicological studies like tumor induction by carcinogens115 or screening toxic 
compounds116. In drug delivery, zebrafish are used for screening of macrophage 
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clearance117, and nanomedicines118, or identifying off-target drug effects119. 
Especially for human disease models, zebrafish embryos suit very well because of 
their gene mutations that are orthologous to human disease genes with clear 
phenotypic similarities as a result100. With that, zebrafish are able to act as a pre-
screening model prior to animal experiments and are reducing animal experiments in 
compliance with the 3R - Replace, Reduce, Refine – principle120,121. 
 
III. IMAGING TECHNIQUES 
The history of microscopy started around 1021 AD. Muslim medieval physicist Ibn al-
Haytham (Alhazen) wrote the seven-volume “Book of Optics” (Kitab al-Manathir) 
which “hugely influenced thinking across disciplines from the theory of visual 
perception to the nature of perspective in medieval art, in both the East and the West, 
for more than 600 years”122. The “Book of Optics” was then translated into Latin in 
the early 13th century, as “De Aspectibus”. This work was a basis in this field and 
influenced the future research tremendously. In the 11th century, the Arab world used 
plano-convex lenses made out of polished beryl which were used for magnifying 
manuscripts. Starting from this point, the first compound microscopes with an 
adjustable magnification of 3 or 9 X were built in the 16th century by the Dutch 
spectacle maker Hans Janssen and his son Zacharias followed by Galileo Galilei in 
1609, who built a microscope out of a telescope123. Inspired from this, Johannes 
Kepler had the idea to create a microscope consisting of two converging lenses which 
was presented by the astronomer Cornelius Drebbel. The first publication about 
microscopes came out 1667 from the English universal scholar Robert Hooke with 
various studies using microscopes124. Antonie van Leeuwenhoek analyzed in 1674 
some lake water and discovered bacteria which was a milestone125. The microscopes 
were further improved and 1863, the Ernst Leitz microscope manufacturer company 
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introduced the first revolving turret with more than five objectives. In 1869, Ernst Abbe 
who was working for Zeiss Optical Works, founded by Carl Zeiss, invented the new 
patented illumination device called the Abbe condenser that was the basis for 
immersion objectives126. 
 
Table 3 - Overview of different imaging techniques, their spatial resolution, scan time, used contrast agents, 
and their area of application (changed from127) 
 
 
Today, we have a broad variety of different imaging techniques (Table 3). They all 
differ in their spatial resolution, area of application, scan time, and also with the usable 
contrast agents127. In the following chapters, the imaging techniques used in this work 
are further explained in more detail. 
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LIGHT AND FLUORESCENCE MICROSCOPY 
 
LIGHT MICROSCOPY 
The light microscope has a mechanical construction made of different pieces. One of 
the more advanced devices is the compound microscope. Here, an objective lens 
close to the viewed sample is used and applying light for illumination, the sample is 
magnified and visible inside the microscope. Together with the eyepieces, 
magnifications up to 2000 times are possible128. In light microscopy, the illumination 
source and the objectives are on different sides of the sample, so the light needs to 
pass through the specimen for visualization. Because of the thin sample layers, low 
amounts of light is absorbed which leads to a low contrast129. To overcome this, 
phase contrast and differential interference contrast (DIC) techniques are used. 
Phase contrast increases the contrast by showing i.e. cells darker on a bright 




Instead of light, also fluorescent dyes in combination with an excitation and emission 
wavelength can be used to see different fluorescent structures in the sample. The 
structures are visible either by genetical modification with a fluorescent protein or by 
manual fluorescent labeling with fluorescent antibodies (immunofluorescence). Also 
multiple fluorescent structures can be visualized at once by using different 
wavelengths with the respective fluorophores128. An overview of different fluorescent 
proteins can be found in Table 4. 
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Table 4 – Overview of different fluorescent proteins and their excitation and emission 
wavelengths, molar extinction coefficients (EC), quantum yields (QY), physiological 




The operation of the electron microscope is similar to the light microscope but the 
illumination source is substituted by an electron beam. Instead of glass lenses, 
electromagnetic and -static lenses are used128. The samples are specially prepared 
by staining with uranyl acetate or lead citrate to make a thin layer of electron-dense 
material on top of the specimens132 and are placed on special metal grids made out 
of copper or other metals with a grid mesh size between 100 and 400. Samples need 
to be very thin which is achieved by using i.e. the Porter Bloom microtome that is able 
to cut 1 µm or ultrathin 40-60 nm histological sections133. Mainly, two different imaging 
methods are available, transmission electron microscopy (TEM) and scanning 
electron microscopy (SEM). TEM is mostly used for characterization of morphology, 
crystalline structures, membrane materials, or nanoparticles134,135. Nowadays, even 
tomography is possible with TEM, which is scanning a sample layer-by-layer and 
merging the images at the end to a 3D object. A disadvantage of this method is the 
appearance of artifacts136. In comparison to TEM, SEM is providing for the upper 1 
µm layer of a sample an analysis of the surface topography, crystalline structures, 
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chemical composition and electrical behavior with magnifications up to 1 million times 
with an ultimate resolution of 1 nm137. Another method is the cryo-electron microscopy 
(cryo-EM) in which biological samples can be rapidly frozen, allowing visualization of 
organic macromolecules or soft matter materials like organic compounds, for 
example liposomes, in near-native environments138. 
 
CONFOCAL LASER SCANNING MICROSCOPY   
There are several different types of confocal laser scanning microscopes (CLSMs). 
They are able to remove appearing blur from outside of the focal plane of images139. 
The principle can be explained as a laser beam light which is focused to a small area 
on the specimen. At this spot, the fluorophores are excited and the fluorescent 
emission is then reflected on a detector through a variable pinhole. Here, the 
fluorescence is measured on this specific in-plane focus spot which is becoming 1 
pixel in the image afterwards. By moving the focused spot and repeating the whole 
procedure, an entire image of the specimen is created pixel-by-pixel. By changing the 
focal plane, 3D scans can be acquired which will give depth information of the 
specimen (acquisition of z-stacks). Another factor is the scan speed. Slower scan 
speeds result in better signal to noise ratios (S/N) because each pixel intensity will be 
integrated longer. At the same time, photobleaching of the fluorophores will also 
increase139. Therefore, the goal should be to gather images quantitatively with 
maximal S/N without clipping the data140. 
 
MICRO(SCOPIC) COMPUTED TOMOGRAPHY (MICRO-CT OR µCT) 
The invention and usage of the µCt goes back to the 1980s where it is described as 
a “new technique of x-ray microtomography generates nondestructively three-
dimensional maps of the x-ray attenuation coefficient inside small samples with 
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approximately one percent accuracy and with resolutions approaching one 
micrometer”141. Usually the system consists of a high-resolution imaging detector and 
of high-speed algorithms for generating the tomographic 3D reconstruction141,142. CT 
is a 3D X-ray imaging method where the sample is being rotated around the vertical 
or horizontal axis and many 2D images (image stacks) are generated. Those images 
made out of pixels (x µm2) are then calculated back to the full 3D sample with internal 
structures by reconstruction defined by voxels (x µm3). The µ in µCt  stands for the 
submillimeter voxel resolution which is possible with these devices with spatial pixel 
resolutions between 12 and 50 µm (Table 3)143. The µCt has three main components: 
X-Ray source, X-Ray detector panel, and integrated algorithms to overcome 
hardware limitations and make reconstructions out of projections (Figure 7)143.  
 
 
Figure 7 – Schematic representation of X-ray (µ)CT acquisition and reconstruction. X-rays 
going through the sample which is on a rotation stage and detected by a photo detector. 
The series of projection images are then reconstructed to a 3D volume which is made of 2D 
slices (copied from144) 
 
The µCt imaging is based on X-ray absorption of different materials depending on 
their electron density. This makes it possible to identify different structures of a 3D 
sample by plotting the voxel intensities (x-axis) against the number of voxels (y-axis). 
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The less dense structure peaks will be seen on the left, and the higher dense structure 
peaks on the right side of the x-axis (voxel intensity histogram)144. Based on this 
histogram, it is possible to segment the digital 3D volume of the sample in different 
components (intensity-based segmentation). Because samples with soft tissue have 
a very similar absorption, it can be difficult to segment them based on their density. 
For this reason, it can be helpful to either use contrast agents or to use a method with 
a high flux like the synchrotron radiation with more details in the next chapter145.  
 
SYNCHROTRON 
The synchrotron radiation X-Ray µCT has increased benefits compared to the usual 
µCT i.e. higher resolution, higher X-ray flux and faster scan times146. If fast speed 




Figure 8 – Scheme of a synchrotron facility with the linear accelerator containing the electron gun and booster 
synchrotron, storage ring, beamlines, optics and experiment cabin, and control room (copied from147) 
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The components of a synchrotron are as shown in Figure 8 a linear accelerator (linac) 
with an electron gun, producing electrons similar to a cathode ray where the electrons 
are pulled out with an energy of 90 kV between cathode and anode. They are 
accelerated up to 200 million electron-volts (MeV) before getting injected into a 270 
to 300 m booster synchrotron ring that accelerates the electrons to a given energy 
(between 2.4 to 6 billion electron-volts (GeV)). The storage ring which is between 288 
844 meters long depending on the facility, is a high-vacuum tube (around 10-9 mbar), 
where the electrons are kept at near speed of light. During this process, the electrons 
pass different magnets like bending magnets, which are at every curved section and 
force the electrons to the path of the tube, focusing magnets which ensure that the 
electrons stay on their ideal orbital path, and the undulators, a complex set of magnet 
arrays, where the intense X-ray beams are produced148,149. The undulators force the 
electrons to a wavy path to generate much more brilliant light beams compared to 
single magnets. The synchrotron light produced at facilities have an energy between 
10 to 120 keV and a wavelength of 0.10 to 0.01 nanometers (ultra-violet to hard X-
Rays). This is so small, that even atoms can be studied due to the closeness to 
interatomic distances150. The beamline itself is built of optics, experimental and 
control cabins. From the beginning to the end, the beamline consists of the source 
(entrance from the storage ring), lits, safety components like beam shutter and beam 
stopper, mirrors with filters to focus and cut away unwanted parts of the spectrum, 
well-polished and highly precise mirrors serving as lenses, and a monochromator for 
selecting a single wavelength made out of crystal followed by the experimental 
cabin151. Also in this method, absorption contrast is very weak between organic 
compounds in vivo and because of this, phase contrast imaging is used to enhance 
the contrast drastically by exploring the refractive index of the components152. To 
study larger animals, the body still needs to be sacrificed to examine single organs 
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or tissue areas. For smaller animals like C. elegans or Danio rerio, it is possible to 
analyze the whole sample non-destructively as a whole 3D model to see i.e. 
nanoparticle distributions152,153. This was also done in this work by using Danio rerio 
embryos to analyze the hybrid nanoparticle in vivo biodistribution by using 
synchrotron radiation X-ray µCT phase-contrast imaging and segmentation of the 
reconstructed digital 3D volume of the samples.  
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CHAPTER 3: AIM OF THE THESIS 
The usage of nanoparticles in general, especially in drug delivery, imaging, and 
theranostics, is increasing since years. Therefore, one of the main questions of this 
thesis was how to ensure the safe usage of those nanoparticles and try to group them 
in populations with similar toxicity profiles and behaviors to make predictions by 
screenings in future. Out of a broad variety of different nanoparticles, 
superparamagnetic iron oxide nanoparticles and liposomes were chosen to create 
hybrid nanoparticles with characteristics of both groups. An electron dense and 
superparamagnetic core makes magnet-driven targeted drug delivery, in vivo 
imaging, and target-site manipulation like local hyperthermia possible.  The liposome-
coating is additionally modifiable with different targeting or imaging agents, peptides, 
polymer additions like PEG to increase stability, and lipo- or hydrophilic drug loading. 
So the second goal of this thesis was to establish a stable method to produce those 
hybrid nanoparticles, characterize them and use them for imaging and biodistribution 
studies in a small vertebrate animal model (Danio rerio). A short summary of the aims 
are: 
 
• Evaluation of existing nanoparticle safety guidelines and working out a new guideline 
for intravenously applied clinical nanoparticles  
 
• Working out a solid synthesis method for SPION/liposome hybrid nanoparticles, 
characterization, and analysis of biodistribution by imaging Danio rerio embryos with 
different methods including synchrotron µCT 
 
• In vivo targeting with SPION/liposome hybrid nanoparticles and manipulation of 
those by magnetic fields and acoustic waves 
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CHAPTER 4: RESULTS 
 
The results of this thesis were published / submitted* in the following journals: 
 
1) Preclinical hazard evaluation strategy for nanomedicines, Cörek et al. 
(shared first author), Nanotoxicology, 13:1, 73-99 (2019) 
 
2) Shedding Light on Metal-Based Nanoparticles in Zebrafish by Computed 
Tomography with Micrometer Resolution, Cörek et al., SMALL (2020) 
 
3) Magnetic field induced phagocytosis of iron oxide nanoparticles in zebrafish 
embryo (Danio rerio), Cörek et al.* 
 
4) Further publications as Co-Author: 
 
• Removing ring artefacts from synchrotron radiation-based hard x-ray 
tomography data, Thalmann et al., SPIE Proceedings (2017) 
• Propagation-based X-ray Phase Contrast Microtomography of 
Zebrafish Embryos to Understand Drug Delivery, Schulz et al., 
Microscopy and Microanalysis (2018) 
• An Introduction to Synchrotron Radiation: Techniques and 





*will be submitted to a journal, work in progress  
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Emre Cörek (shared first author), Stefan Siegrist (shared first author), Pascal Detampel, 
Jenny Sandström, Peter Wick, Jörg Huwyler 
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II. Shedding Light on Metal-Based Nanoparticles in Zebrafish by Computed 




Emre Cörek, Griffin Rodgers, Stefan Siegrist, Tomaz Einfalt, Pascal Detampel, Christian 
M. Schlepütz, Sandro Sieber, Pascal Fluder, Georg Schulz, Harald Unterweger, Christoph 
Alexiou, Bert Müller, Maxim Puchkov, Jörg Huwyler 
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III. MAGNETIC FIELD INDUCED PHAGOCYTOSIS OF IRON OXIDE NANOPARTICLES IN 




Emre Cörek, Tomaz Einfalt, Jan Stephan Bolten, Jörg Huwyler 
 
 
Journal: will be submitted a journal as a short communication paper 
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CHAPTER 5: DISCUSSION AND CONCLUSION 
 
The first goal of this PhD thesis was the implementation of a hazard evaluation 
assessment strategy for nanoparticles in cooperation with the Swiss Centre for 
Applied Human Toxicology (SCAHT) and the Swiss Federal Laboratories for 
Materials Science and Technology (EMPA) that was part of the NanoREG II 
European Union’s Horizon 2020 research and innovation program (Chapter 4: 
Results, I). To fill the gap of missing regulatory guidelines for IV applied nanoparticles 
for drug delivery, imaging and theranostics, “Preclinical hazard evaluation strategy 
for nanomedicines”79 was written and published. Further on, as a second goal, 
implementation of a hybrid nanoparticle tool box was determined (Chapter 4: Results, 
II). A small vertebrate animal model (Danio rerio) was used for in vivo analysis of the 
fate of IV applied nanoparticles by imaging with various methods and comparing 
thereof. The main steps before the application were nanoparticle synthesis, 
modification, and characterization. In two beamtimes at the European Synchrotron 
Radiation Facility (ESRF) and Paul Scherrer Institut (PSI), nanoparticle imaging in 
zebrafish embryos was carried out by synchrotron radiation X-ray µCT. The results 
were analyzed and evaluated with 3D data visualization and analysis software to have 
insights into the digital 3D volume of the specimen and the nanoparticle biodistribution 
in vivo including digital histology. Finished was the thesis with experiments on 
magnetic manipulation of hybrid nanoparticles in vivo for macrophage targeting and 
increasing phagocytosis (Chapter 4: Results, III). Also, the possibility of controlling 
those nanoparticles in vivo was shown with electromagnetic accumulation and 
acoustic wave rotation. 
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I. IMPLEMENTATION OF A HAZARD EVALUATION STRATEGY FOR INJECTABLE 
NANOPARTICLES 
 
As an introduction into the world of nanomaterials, a detailed analysis and evaluation 
of different nanoparticle testing strategies was done. The common approaches are 
trying to group nanomaterials based i.e. on their characteristics, dosimetry, 
functionality, and other factors154–158. Those concepts were not specified to certain 
nanoparticle types but more to specific scenarios like workplace exposure via 
inhalation. The purpose was to screen and make risk assessment to a broad range 
of nanoparticles by categorizing them into different groups or simply to be able to tell, 
if they are safe or not for usage. This should help to make i.e. easier predictions in 
the future in terms of workplace safety.  For the injectable nanoparticles used in the 
clinics, there was no specific guideline. One of the most important issues in research 
is the implementation of the 3R principle for animal welfare159. To fulfil these criteria 
and improve existing guidelines, the hazard evaluation strategy for injectable 
nanoparticles (HES) was proposed (Chapter 4: Results, I). This approach should 
serve as a good alternative to existing approaches especially in terms of 
nanomedicines. To show the potential, a theoretical comparison between selected 
grouping approaches was done. This showed, that HES is testing the highest number 
of experimental parameters (Table 5) and is the only approach which is based on 
cellular uptake and cellular persistence, in case of injectable nanomedicines the most 
important factors. At the same time, HES is not a screening approach but uses 
decision pathways to minimize needed experiments. In future, this testing approach 
needs to be practically tested by different independent research groups and 
evaluated to have a statistical proof, that it is really easing up i.e. preclinical safety 
evaluations and helping as a basis protocol to group nanoparticles. For this goal, the 
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existing HES guideline can be further improved and extended to other nanoparticle 
types or combined with new approaches to implement a whole cascade which ideally 
gets the new international testing standard accepted by the regulatory authorities.  
 




II. DEVELOPMENT OF A HYBRID NANOPARTICLE TOOLBOX FOR IN VIVO EXPERIMENTS 
 
Nanoparticles can be used for a variety of different purposes because of their broad 
range of properties and advantages. The selection of the most suitable nanoparticle 
is getting easier with the amount of publications increasing every day. One faction, 
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the hybrid nanoparticles, are used since years to combine different characteristics 
and improve the application properties i.e. for cancer treatment160. Instead of having 
two different steps for imaging and treatment, it is possible to combine those methods 
with the right hybrid nanoparticles to a single approach, called theranostics161. 
Usually, metal nanoparticles are used for the purpose of imaging with their dense 
cores coated with i.e. liposomes162. This has the advantage, that the coating serves 
as a protective layer that will stealth the nanoparticles in vivo from the immune system 
and at the same time gives a lot of possibilities to modify them i.e. by drug loading for 
therapy purposes163. SPIONs were chosen as metal cores because of their proven 
properties in literature as contrast agents with the ability for manipulation i.e. by 
magnetically direct them towards a target, and also induce hyperthermia at the target 
site for temperature-controlled drug release or physical therapy of tumors164–166. 
Compared to other nanoparticles, SPIONs are cheap and straight forward to 
synthesize, have a narrow size distribution and excellent properties such as 
superparamagnetism. To use them as injectables and prevent agglomeration, they 
need to be coated with protective layers like citric acid or in this case liposomes. In 
this work, a new coating method was analyzed and implemented by using 
microfluidics. As a result, SPIONs coated with liposomes were generated which had 
good physicochemical properties. This new method proved itself to be stable and 
served therefore as a “tool box” for a variety of modifications i.e. by pegylation with 
different molecular weight PEG chains from 350 to 5000 and folic acid for renal 
targeting by binding to the folate receptor. Disadvantages of this method could be the 
need of a microfluidics system (i.e. NanoAssemblr®) which needs to be bought first. 
For future research, this tool box can be further validated by generating new hybrid 
nanoparticles by modifying the coating and loading them also with different drugs for 
theranostic purposes. 
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III. CHARACTERIZATION AND IN VIVO EXPERIMENTS WITH HYBRID NANOPARTICLES IN A 
SMALL ANIMAL VERTEBRATE MODEL (DANIO RERIO) 
 
Physicochemical characterization was done for every used nanoparticle in this work 
by the basic methods such as transmission electron microscopy, dynamic light 
scattering, and electrophoretic light scattering167. Core size, hydrodynamic size, 
polydispersity index (PDI), and zeta potential were determined as a qualitative control 
and to gather statistically solid results (Table 6, Figure 9).  
 
Table 6 – Some physicochemical characterization results of nanoparticles used 
throughout of this PhD thesis. AuNP are gold nanoparticles, SPIONs are iron 
oxide nanoparticles coated with human serum albumin, lipoSP are hybrid 
nanoparticles made out of SPIONs and liposomes with the polyethyleneglycol 
peg chain length given in molecular weight as a number (350, 2000, 5000). All 








AuNP 29.6 ± 0.1 0.19 ± 0.2 -29.4 ± 0.8 
AuNP in FCS 94.9 ± 2.1 0.31 ± 0.5 -10.6 ± 0.9 
SPIONs 61.0 ± 0.3 0.13 ± 0.01 -24.9 ± 1.0 
SPIONs in FCS 60.7 ± 0.3 0.19 ± 0.02 -14.38 ± 0.9 
lipoSP w/o PEG 122.3 ± 1.9 0.29 ± 0 -23.4 ± 0.8 
lipoSP w/o PEG 
in FCS 
126.5 ± 24.1 0.29 ± 0.01 -9.35 ± 0.8 
lipoSP-PEG350 131.2 ± 4.5 0.21 ± 0.07 -29.6 ± 0.5 
lipoSP-PEG350 
in FCS 
241.7 ± 88.6 0.20 ± 0.05 -34.4 ± 26.4 
lipoSP-
PEG2000 
105.2 ± 0.7 0.30 ± 0.01 -4.0 ± 0.4 
lipoSP-
PEG2000 in FCS 
173.1 ± 71.6 0.24 ± 0.06 -6.1 ± 0.5 
lipoSP-
PEG5000 
122.0 ± 1.2 0.28 ± 0.01 0.4 ± 0.3 
lipoSP-
PEG5000 in FCS 
97 ± 2.8 0.39 ± 0.03 4.6 ± 0.1 
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Figure 9 - Transmission electron microscope (TEM) images of ENPs. Figure 1 shows TEM images of 
different nanoparticles used in this work. Gold nanoparticles coated with citric acid (A), lipophilic iron 
oxide nanoparticles without PEG (B), lipophilic iron oxide nanoparticles with PEG 2000 (C), iron oxide 
nanoparticles coated with lauric acid and human serum albumin (D), lipophilic iron oxide nanoparticles 
with PEG 350 (E), and lipophilic iron oxide nanoparticles with PEG 5000 (F). The core of the 
nanoparticles is visible in black/dark grey and the surrounding lipid layer is visible as a bright hollow 
around the core. The nanoparticles were all synthesized as described in the Material and Methods 
section of this work. Scale bars = 100 nm each. 
 
Methods such as dialysis for purification, UV-Vis for concentration determination, and 
multiple long-term measurements of size and PDI for long-time stability were used. 
Cytotoxicity measurements were conducted with different cancer and macrophage 
cell lines like HepG2 or THP-1 with MTT- or Alamar blue assays. Uptake was 
measured by flow cytometry and confocal laser scanning microscopy (CLSM) (Figure 
10).  
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Figure 10 - CLSM uptake and FACS (inhibitory) uptake results of lipoSPIONs with THP-1 cells. Upper 
row shows the lipoSPIONs uptake into THP-1 cells after 3 hours by CLSM. From left to right are 
LipoSPIONs without PEG (a), lipoSPIONs with PEG 350 (B), lipoSPIONs with PEG 2000 (C) and 
lipoSPIONs with PEG 5000 (D). The fluorescent DiI lipoSPIONs are shown in red, the fluorescent 
Hoechst nuclei in blue. Uptake data analyzed by FACS is shown on the bottom row. Cells were incubated 
with lipoSPIONs without PEG, with PEG 350, PEG 2000, and PEG 5000 for 1, 3, 6 and 24 hours (e) and 
untreated controls. 1 hour uptake is shown in red, 3 hours uptake in yellow, 6 hours uptake in violet, and 
24 hours uptake in green color and controls in black. Y-axis shows the amount of DiI positive cells. 
Inhibitory uptake experiments after 4 hours incubation with lipoSPIONs without PEG in pink and with 
lipoSPIONs with PEG 5000 in olive is shown in (f). Controls without inhibitors with lipoSPIONs without 
PEG is shown in violet and with lipoSPIONs with PEG 5000 in blue. Untreated controls are shown in 
black. Abbreviations: woP= without PEG; P350 = PEG 350; P2000= PEG 2000; P5000= PEG 5000; 
CytoB= Cytochalasin B; PI acid= Polyinosinic acid; ct= control. Statistically significance is given with one 
asterisk for p≤ 0.05 and with two asterisks for p≤ 0.01. Scale bars= 60 nanometer each.     
      
To be able to detect the hybrid nanoparticles by fluorescence imaging, they were 
modified with the fluorescent dye DiI. Lower uptake was detected for pegylated 
nanoparticles with long molecular weight PEG chains fitting with the literature168,169. 
The nanoparticles were not cytotoxic in the used concentrations up to 180 ppm. For 
in vivo studies of those hybrid nanoparticles, zebrafish embryos (Danio rerio) were 
used as an established small vertebrate model common for toxicity, imaging, and 
drug delivery studies170,171. The results of the in vitro and in vivo studies correlated in 
terms of uptake and cytotoxicity imaged by light microscopy by dual injection of 
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Prussian blue mixed with nanoparticles. Dark-blue pigmentation showed an intact 
coating after a certain time probably by degradation inside macrophages. CLSM 
showed the co-localization of green fluorescent macrophages of the zebrafish 
embryo strain mpeg:kaede with the red fluorescent signal of the nanoparticles. Again, 
longer PEG chains lead to lower uptake after various timepoints up to 72 hours post 
injection which was detected by co-localization (Chapter 4: Results, II,III). Also, folic 
acid modified hybrid nanoparticles were used for renal targeting. First results can be 
seen in Figure 11. Because the access to a zebrafish strain with fluorescent renal 
system was not possible, no further co-localization analysis could be done. This can 
be repeated in the future, when access to such a strain is given.  
 
Figure 11 – Zebrafish embryo of the strain mpeg:kaede with fluorescent 
macrophages. Folic acid modified hybrid nanoparticles were injected into zebrafish 
embryos 48 hpf and analyzed by CLSM. Upper picture shows a whole zebrafish 
embryo with the cut out area marked in yellow dotted lines. Pictures in the middle 
section with the red dotted lines show embryos with injected folic acid nanoparticles 
with an accumulation in the renal region of the embryo. Lower images show embryos 
with injected control particles without folic acid with no agglomeration. 
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The whole results proved, that the nanoparticles are stable in vitro and in vivo and 
the tool box can be applied for future experiments. This was important for establishing 
one of the main goals in the beginning of the thesis because without this, all of the 
following experiments could not be done. 
 
IV. TESTING VARIOUS IMAGING METHODS INCLUDING SYNCHROTRON X-RAY µCT 
 
As mentioned in the earlier part, imaging with light and confocal laser scanning 
microscopy was possible with the hybrid nanoparticles. The idea was to have a full 
3D distribution analysis of the nanoparticles in vivo. Although this is partly possible 
with CLSM (z-stacks), the z-axis resolution is not very satisfying because of the 
thickness of the embryos and also the nanoparticles need to be modified with 
fluorescent dyes. This leads to the situation that their physicochemical properties may 
be affected172. Fluorescent labeling is also not possible with nanomedicines because 
when particles are produced with GMP guidelines like the SPIONs coated with 
dextran or human serum albumine which we received from Prof. Dr. Alexiou’s 
research group from Erlangen, the modification will not guarantee anymore the proper 
function. To overcome this problem, together in a collaboration with the group of Prof. 
Dr. Bert Müller, µCT was tested with the nanotom®m device. Detection of 
nanoparticles ex vivo was possible.  
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Figure 12 - Control experiments. To ensure detection of 
AuNP and SPIONs is possible in nanotom®m. The 
background is visible in black, the Eppendorf tubes in 
grey. White areas showing dense materials like the 
AuNP and SPIONs, whereby higher intensities are 
equal to higher densities. Eppendorf tubes containing: 
control with paraffin and water (1), gold nanoparticles c= 
3.3 mg/ml (2), SPIONs c= 5.6 mg/ml (3), silica 
nanoparticles c= 20 mg/ml (4), silica nanoparticles c= 
10 mg/ml (5), lyophilized gold nanoparticles (6), paraffin 
and filter paper (7), and paraffin (8). 
 
Also, the imaging of zebrafish embryos was possible although with bad quality and 
resolution (Figure 13)173.  
 
 
Figure 13 - μCT analysis of a 48 hpf zebrafish embryo. Nanoparticles could not be 
detected during trials performed with the nanotom®m. Otholits serve as orientation 
points (B, red structures), since zebrafish embryos did not develop any bony 
structures in this developmental stage. Scale bars: 100 μm (A) and 50 μm (B) 
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The idea to improve this situation was to use synchrotron radiation X-ray µCT with its 
higher X-ray flux174. Two beamtimes were used, ESRF and PSI. In the first round, 
various different nanoparticles like silica, gold and iron oxide in different 
concentrations were tested in vivo in zebrafish embryos which were post mortem 
analyzed at 24 and 48 hpi. Because of the known disadvantages of absorption 
contrast in soft tissue due to low contrast differences (Figure 14), phase-contrast 




Figure 14 - Contrast differences in μCT. Uncorrected projection (A), 
flat- and dark-field corrected absorption contrast projection (B), and 
flat- and dark-field corrected phase contrast (C) images of a 96 hpf 
zebrafish embryo embedded in paraffin. Introducing flat- and dark-field 
corrections lead to the subtraction of background noise in the 
reconstructed projections. Absorption contrast images show higher 
sharpness and lower contrast. Phase contrast images show lower 
sharpness and higher contrast, which is more suitable for soft tissue 
imaging. Scale bars: 250 µm each 
 
From the received projections of the samples, a reconstruction was done with 
different algorithms like the Paganin filter176. With help of the delta-beta value, the 
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contrast can be adjusted which can either be set by trial-and error or calculated 
depending on the experiment (Figure 15)177.  
 
Figure 15 – Phase-contrast reconstruction phase-retrieval image of a 96 hpf zebrafish 
embryo with increasing delta-beta values from left to right showing the contrast change. 
Values are from left to right are: 100-200-300-500-800-1000-1500-2000. 
 
The field-of-view during the imaging was not enough at 40x for the whole sample, so 
multiple height scans needed to be done to capture the whole embryo. After the 
reconstruction of all height steps, they were manually stitched together via Fiji 
imaging software. 3D digital volume analyses were done with reconstruction software 
Avizo. The results were evaluated and iron oxide nanoparticles were chosen because 
the other nanoparticles couldn’t be detected or i.e. gold stick quickly to the injection 
side and showed no biodistribution. This was the successful proof-of-concept study, 
that detection of iron oxide nanoparticles in zebrafish embryos, which was not shown 
in this combination before, was possible (Figure 16).  
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Figure 16 - 3D reconstructions of zebrafish embryos showing the biodistribution of 
AuNP and SPIONs. 3D reconstructions of synchrotron phase contrast projections of 
1 hpi zebrafish embryos. Injections of 5 nl AuNP (c= 3.3 mg/ml, RI: 0.2) and 5 nl 
SPIONs (c= 5.6 mg/ml: RI: 2.93) were performed into the Duct of Cuvier (DoC). The 
depictions show the zebrafish embryos (grey), AuNP (yellow), SPIONs (red), and 
Otoliths (blue). Opaque embryos with body surface (A, C) and transparent embryos 
with inner structures (B, D) highlight that both ENP reside inside the specimens. 
AuNP adhere to the surrounding tissue of the injection side (DoC). SPIONs are found 
to adhere less to the same tissue. However, they are clearly visible in the areas of 
the anterior cardinal vein (ACV), posterior cardinal vein (PCV), and the dorsal aorta 
(DA). Scale bars = 100 µm (A, B); 50 µm (C, D). 
 
For the next beamtime, PSI was chosen because of a maintenance shutdown of the 
ESRF. Now, only differently pegylated hybrid nanoparticles were injected at the same 
dose and embryos were 24 and 48 hpi post mortem fixed. Dextran and human serum 
albumine coated SPIONs were used as long- and short circulating controls178–180. It 
was possible to show, that there is a strong accumulation of short peg chain 
nanoparticles and human serum albumine coated SPIONs in the vasculature, 
opposite of the Dextran coated SPIONs and long chain nanoparticles that is also 
described in the literature181. It was shown, that the results (maximal intensity on the 
x-y axis) of CLSM and synchrotron are consistent.  
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Advantages of the synchrotron were: 
• outrageous resolutions in all three axes,  
• simultaneous analysis of nanoparticle biodistribution and histology,  
• faster imaging speed,  
• full digital histology qualitatively comparable to classical histology methods 
by slicing and staining of the fixed specimen but with the advantage of not 
destroying the sample which can be further used for additional experiments.  
 
Disadvantages are difficulties to get beamtimes because of limited resources and 
time-consuming analysis of the results with requirement of high-end computers. 
Nevertheless, for the future, it is possible to further tune this whole set up i.e. for 
tissue biopsy analysis. If done right, computer scientists can help by automating the 
whole reconstruction and analysis process, so that only a mouse-click is needed after 
loading in the data to receive the results. Also, it is possible that with modern 
developments in the future, high-flux devices can be also available as compact light 
sources for scientists182 (Chapter 4: Results, II).  
 
V. MAGNETIC AND ACOUSTIC MANIPULATION OF NANOPARTICLES IN VIVO 
 
One of the advantages of SPIONs is their characteristics allowing magnetic 
manipulation in vivo. By using external magnetic fields such as bar magnets, the 
behavior of the particles will change and this will i.e. lead to higher uptake in cells. In 
this work, we used an external magnetic field to increase phagocytic uptake. The long 
circulating hybrid nanoparticles with PEG chains of molecular weight 5000 were 
injected and manipulated in zebrafish embryos with help of a strong bar magnet. As 
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a result, the phagocytic uptake increased significantly compared to control group 
without magnetic manipulation. Macrophage targeting was described in the literature 
as a treatment method for various diseases183. With help of the zebrafish embryo, the 
hybrid nanoparticle tool box, and magnetic manipulation, those effects can be further 
analyzed i.e. by loading the particles with different drugs for treatment of the 
respective diseases like inflammation and cancer. Addiitonally, electromagnetic fields 
and acoustic waves were used in a further unpublished experiment, in which it was 
possible to agglomerate fluorescent SPIONs in vivo and rotate them with help of 
acoustic waves (Figure 17). Studies with nanorobots were already done ex vivo184–
186 but in an animal model, this was not shown before and opens possibilities to use 
i.e. nanorobots in zebrafish embryos in proof-of-concept studies in the future187,188.  
 
 
Figure 17 - Trapping and rotation of SPIONs in vivo. Schematic overview of a 50 hpf zebrafish embryo on upper 
image with the position of the trapped SPIONs marked with a red star. Brightfield image of the zebrafish embryo 
with the trapped SPIONs marked with a red star in circle (BF) with the otholits (O), spine (S), and yolk (Y). Images 
A to D show snapshots from the video with the trapped SPIONs marked with a red arrow (2 hpi) rotating first in 
the clockwise direction (from A to B) and later in the counterclockwise direction (from C to D). The trapping and 
rotation of the SPIONs is controlled by an electro magnet and acoustics chamber which is possible with a special 
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CHAPTER 6: OUTLOOK 
 
For the future, different aspects of this thesis can be extended. Because the subject 
with nanoparticle safety will also be important in the future, our HES approach can be 
further analyzed, evaluated, and combined with new or existing approaches to further 
improve the outcomes. Also the hybrid nanoparticle tool box offers possibilities for 
many different new particles which can be created easily in laboratories as described 
in the methods of Chapter 4: Results, II for future research. Evaluation of the targeting 
possibilities in vivo by continuing the renal targeting with the folic acid particles can 
be done or new ligands or antibodies can be used i.e. for blood brain barrier targeting. 
Another aspect would be to continue with magnetic manipulation experiments for 
macrophage targeting or even electromagnetic aiming of different anatomical 
structures which was also not shown yet in zebrafish embryos as a model organism 
yet.  This would fill the gap between in vitro experiments and in vivo studies in higher 
vertebrates. More futuristic is the idea of using nanorobots inside vertebrates for drug 
delivery and targeting with tremendous possibilities for what this experiment made 
the basis as a first proof-of-concept result. 
 
  
120 |  
 
REFERENCES 
1. Faraday, M. X. The Bakerian Lecture. —Experimental relations of gold (and other 
metals) to light. Philos. Trans. R. Soc. Lond. 147, 145–181 (1857). 
2. Leonhardt, U. Invisibility cup. Nat. Photonics 1, 207–208 (2007). 
3. Caiger-Smith, A. Lustre pottery: technique, tradition, and innovation in Islam and 
the Western world. (Faber and Faber, 1985). 
4. From Nanotech to Nanoscience. Science History Institute 
https://www.sciencehistory.org/distillations/magazine/from-nanotech-to-
nanoscience (2016). 
5. Knoll, M. & Ruska, E. Das Elektronenmikroskop. Z. Für Phys. 78, 318–339 (1932). 
6. Hawkes, P. W. The Beginnings of Electron Microscopy. (Academic Press, 2013). 
7. Heiligtag, F. J. & Niederberger, M. The fascinating world of nanoparticle research. 
Mater. Today 16, 262–271 (2013). 
8. Hartland, A., Lead, J. R., Slaveykova, V., O’Carroll, D. & Valsami-Jones, E. The 
Environmental Significance of Natural Nanoparticles. Nat. Educ. Knowl. 4, 7 
(2013). 
9. Shi, Z., Shao, L., Jones, T. P. & Lu, S. Microscopy and mineralogy of airborne 
particles collected during severe dust storm episodes in Beijing, China. J. 
Geophys. Res. Atmospheres 110, (2005). 
10. Fedotov, P. & Ermolin, M. Nanoparticles of volcanic ash as a carrier for toxic 
elements on the global scale. EGU Gen. Assem. Conf. Abstr. 2373 (2018). 
11. Sapkota, A. et al. Impact of the 2002 Canadian Forest Fires on Particulate 
Matter Air Quality in Baltimore City. Environ. Sci. Technol. 39, 24–32 (2005). 
12. Buseck, P. R. & Pósfai, M. Airborne minerals and related aerosol particles: 
Effects on climate and the environment. Proc. Natl. Acad. Sci. 96, 3372–3379 
(1999). 
| 121   
 
13. Jeevanandam, J., Barhoum, A., Chan, Y. S., Dufresne, A. & Danquah, M. K. 
Review on nanoparticles and nanostructured materials: history, sources, toxicity 
and regulations. Beilstein J. Nanotechnol. 9, 1050–1074 (2018). 
14. Kagawa, J. Health effects of diesel exhaust emissions—a mixture of air 
pollutants of worldwide concern. Toxicology 181–182, 349–353 (2002). 
15. Ning, Z., Cheung, C. S., Fu, J., Liu, M. A. & Schnell, M. A. Experimental study 
of environmental tobacco smoke particles under actual indoor environment. Sci. 
Total Environ. 367, 822–830 (2006). 
16. Stefani, D., Wardman, D. & Lambert, T. The Implosion of the Calgary General 
Hospital: Ambient Air Quality Issues. J. Air Waste Manag. Assoc. 55, 52–59 (2005). 
17. Tan, M.-H., Commens, C. A., Burnett, L. & Snitch, P. J. A pilot study on the 
percutaneous absorption of microfine titanium dioxide from sunscreens. Australas. 
J. Dermatol. 37, 185–187 (1996). 
18. Radwan, I. M., Gitipour, A., Potter, P. M., Dionysiou, D. D. & Al-Abed, S. R. 
Dissolution of silver nanoparticles in colloidal consumer products: effects of particle 
size and capping agent. J. Nanoparticle Res. 21, 155 (2019). 
19. Hochella, M. F. et al. Natural, incidental, and engineered nanomaterials and 
their impacts on the Earth system. Science 363, (2019). 
20. ISO/TS 80004-2:2015(en), Nanotechnologies — Vocabulary — Part 2: Nano-
objects. https://www.iso.org/obp/ui/#iso:std:iso:ts:80004:-2:ed-1:v1:en. 
21. Khan, I., Saeed, K. & Khan, I. Nanoparticles: Properties, applications and 
toxicities. Arab. J. Chem. 12, 908–931 (2019). 
22. Caldorera-Moore, M., Guimard, N., Shi, L. & Roy, K. Designer nanoparticles: 
incorporating size, shape and triggered release into nanoscale drug carriers. 
Expert Opin. Drug Deliv. 7, 479–495 (2010). 
122 |  
 
23. Bhatia, S. Nanoparticles Types, Classification, Characterization, Fabrication 
Methods and Drug Delivery Applications. in Natural Polymer Drug Delivery 
Systems: Nanoparticles, Plants, and Algae (ed. Bhatia, S.) 33–93 (Springer 
International Publishing, 2016). doi:10.1007/978-3-319-41129-3_2. 
24. Hasany, S. F., Ahmed, I., J, R. & Rehman, A. Systematic Review of the 
Preparation Techniques of Iron Oxide Magnetic Nanoparticles. Nanosci. 
Nanotechnol. 2, 148–158 (2012). 
25. Huber, D. L. Synthesis, Properties, and Applications of Iron Nanoparticles. 
Small 1, 482–501 (2005). 
26. Cuyper, M. D. & Joniau, M. Magnetoliposomes. Eur. Biophys. J. 15, 311–319 
(1988). 
27. Cuyper, M. D., Müller, P., Lueken, H. & Hodenius, M. Synthesis of magnetic 
Fe 3 O 4 particles covered with a modifiable phospholipid coat. J. Phys. Condens. 
Matter 15, S1425 (2003). 
28. Bloemen, M. et al. Improved functionalization of oleic acid-coated iron oxide 
nanoparticles for biomedical applications. J. Nanoparticle Res. 14, (2012). 
29. Mahmoudi, M., Sant, S., Wang, B., Laurent, S. & Sen, T. Superparamagnetic 
iron oxide nanoparticles (SPIONs): Development, surface modification and 
applications in chemotherapy. Adv. Drug Deliv. Rev. 63, 24–46 (2011). 
30. Freeman, M. W., Arrott, A. & Watson, J. H. L. Magnetism in Medicine. J. Appl. 
Phys. 31, S404–S405 (1960). 
31. Cunningham, C. H. et al. Positive contrast magnetic resonance imaging of 
cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53, 999–1005 
(2005). 
| 123   
 
32. Meng, J. et al. LHRH-functionalized superparamagnetic iron oxide 
nanoparticles for breast cancer targeting and contrast enhancement in MRI. Mater. 
Sci. Eng. C 29, 1467–1479 (2009). 
33. Kim, J., Piao, Y. & Hyeon, T. Multifunctional nanostructured materials for 
multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev. 38, 
372–390 (2009). 
34. Salaheldin, T. A. Magnetite-vitamin C nanoparticles as a potent route for 
treatment of iron deficiency anemia. J. Nanomedicine Nanotechnol. 
doi:10.4172/2157-7439-C1-056. 
35. Schwenk, M. H. Ferumoxytol: a new intravenous iron preparation for the 
treatment of iron deficiency anemia in patients with chronic kidney disease. 
Pharmacotherapy 30, 70–79 (2010). 
36. Lu, M., Cohen, M. H., Rieves, D. & Pazdur, R. FDA report: Ferumoxytol for 
intravenous iron therapy in adult patients with chronic kidney disease. Am. J. 
Hematol. 85, 315–319 (2010). 
37. McCormack, P. L. Ferumoxytol: in iron deficiency anaemia in adults with 
chronic kidney disease. Drugs 72, 2013–2022 (2012). 
38. Anselmo, A. C. & Mitragotri, S. A Review of Clinical Translation of Inorganic 
Nanoparticles. AAPS J. 17, 1041–1054 (2015). 
39. Puri, A. et al. Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: 
From Concepts to Clinic. Crit. Rev. Ther. Drug Carrier Syst. 26, 523–580 (2009). 
40. Yang, F. et al. Advanced biomaterials for cancer immunotherapy. Acta 
Pharmacol. Sin. 1–17 (2020) doi:10.1038/s41401-020-0372-z. 
41. Pottoo, F. H. et al. Lipid-based nanoformulations in the treatment of 
neurological disorders. Drug Metab. Rev. 0, 1–20 (2020). 
124 |  
 
42. Shankar, R. & Pathak*, M. J. and K. Lipid Nanoparticles: A Novel Approach 
for Brain Targeting. Pharmaceutical Nanotechnology vol. 6 81–93 
http://www.eurekaselect.com/162969/article (2018). 
43. Forssen, E. A. & Tőkés, Z. A. Invitro and invivo studies with adriamycin 
liposomes. Biochem. Biophys. Res. Commun. 91, 1295–1301 (1979). 
44. Blum, R. H. Adriamycin: A New Anticancer Drug with Significant Clinical 
Activity. Ann. Intern. Med. 80, 249 (1974). 
45. Barenholz, Y. (Chezy). Doxil® — The first FDA-approved nano-drug: Lessons 
learned. J. Controlled Release 160, 117–134 (2012). 
46. Zucker, D., Marcus, D., Barenholz, Y. & Goldblum, A. Liposome drugs’ loading 
efficiency: A working model based on loading conditions and drug’s 
physicochemical properties. J. Controlled Release 139, 73–80 (2009). 
47. Fan, Y. & Zhang, Q. Development of liposomal formulations: From concept to 
clinical investigations. Asian J. Pharm. Sci. 8, 81–87 (2013). 
48. Carugo, D., Bottaro, E., Owen, J., Stride, E. & Nastruzzi, C. Liposome 
production by microfluidics: potential and limiting factors. Sci. Rep. 6, 1–15 (2016). 
49. Kastner, E. et al. High-throughput manufacturing of size-tuned liposomes by a 
new microfluidics method using enhanced statistical tools for characterization. Int. 
J. Pharm. 477, 361–368 (2014). 
50. Michelon, M., Oliveira, D. R. B., de Figueiredo Furtado, G., Gaziola de la Torre, 
L. & Cunha, R. L. High-throughput continuous production of liposomes using 
hydrodynamic flow-focusing microfluidic devices. Colloids Surf. B Biointerfaces 
156, 349–357 (2017). 
51. Svenson, S. Clinical translation of nanomedicines. Curr. Opin. Solid State 
Mater. Sci. 16, 287–294 (2012). 
| 125   
 
52. Nguyen Tri, P., Ouellet-Plamondon, C., Rtimi, S., Assadi, A. A. & Nguyen, T. 
A. Chapter 3 - Methods for Synthesis of Hybrid Nanoparticles. in Noble Metal-Metal 
Oxide Hybrid Nanoparticles (eds. Mohapatra, S., Nguyen, T. A. & Nguyen-Tri, P.) 
51–63 (Woodhead Publishing, 2019). doi:10.1016/B978-0-12-814134-2.00003-6. 
53. Toro-Cordova, A. et al. Liposomes Loaded with Cisplatin and Magnetic 
Nanoparticles: Physicochemical Characterization, Pharmacokinetics, and In-Vitro 
Efficacy. Mol. J. Synth. Chem. Nat. Prod. Chem. 23, (2018). 
54. Ye, H. et al. Combination of gemcitabine-containing magnetoliposome and 
oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible 
mechanism with potential for clinical application. Oncotarget 7, 43762–43778 
(2016). 
55. Zhu, L. et al. Targeted delivery of methotrexate to skeletal muscular tissue by 
thermosensitive magnetoliposomes. Int. J. Pharm. 370, 136–143 (2009). 
56. Qiu, D. & An, X. Controllable release from magnetoliposomes by magnetic 
stimulation and thermal stimulation. Colloids Surf. B Biointerfaces 104, 326–329 
(2013). 
57. Gonzales, M. & Krishnan, K. M. Synthesis of magnetoliposomes with 
monodisperse iron oxide nanocrystal cores for hyperthermia. J. Magn. Magn. 
Mater. 293, 265–270 (2005). 
58. Huang, H. S. & Hainfeld, J. F. Intravenous magnetic nanoparticle cancer 
hyperthermia. Int. J. Nanomedicine 8, 2521–2532 (2013). 
59. Huang, H.-C., Barua, S., Sharma, G., Dey, S. K. & Rege, K. Inorganic 
nanoparticles for cancer imaging and therapy. J. Controlled Release 155, 344–357 
(2011). 
60. Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for 
drug delivery. Nat. Rev. Drug Discov. 13, 813–827 (2014). 
126 |  
 
61. Nel, A., Xia, T., Mädler, L. & Li, N. Toxic Potential of Materials at the Nanolevel. 
Science 311, 622–627 (2006). 
62. Shvedova, A. A., Kagan, V. E. & Fadeel, B. Close Encounters of the Small 
Kind: Adverse Effects of Man-Made Materials Interfacing with the Nano-Cosmos 
of Biological Systems. Annu. Rev. Pharmacol. Toxicol. 50, 63–88 (2010). 
63. Yildirimer, L., Thanh, N. T. K., Loizidou, M. & Seifalian, A. M. Toxicology and 
clinical potential of nanoparticles. Nano Today 6, 585–607 (2011). 
64. Feliu, N. & Fadeel, B. Nanotoxicology: no small matter. Nanoscale 2, 2514–
2520 (2010). 
65. Wolfram, J. et al. Safety of nanoparticles in medicine. Curr. Drug Targets 16, 
1671–1681 (2015). 
66. Dusinska, M. et al. Testing strategies for the safety of nanoparticles used in 
medical applications. Nanomed. 4, 605–607 (2009). 
67. Seaton, A., Tran, L., Aitken, R. & Donaldson, K. Nanoparticles, human health 
hazard and regulation. J. R. Soc. Interface 7, S119–S129 (2010). 
68. Gebel, T. et al. Manufactured nanomaterials: categorization and approaches 
to hazard assessment. Arch. Toxicol. 88, 2191–2211 (2014). 
69. Mühlebach, S., Borchard, G. & Yildiz, S. Regulatory challenges and 
approaches to characterize nanomedicines and their follow-on similars. Nanomed. 
10, 659–674 (2015). 
70. Scott-Fordsmand, J. J. et al. A unified framework for nanosafety is needed. 
Nano Today 9, 546–549 (2014). 
71. Stone, V. et al. ITS-NANO - Prioritising nanosafety research to develop a 
stakeholder driven intelligent testing strategy. Part. Fibre Toxicol. 11, 9 (2014). 
| 127   
 
72. NANoREG, a common European approach to the regulatory testing of 
nanomaterials | RIVM. https://www.rivm.nl/documenten/nanoreg-a-common-
european-approach-to-regulatory-testing-of-nanomaterials. 
73. Chang, H.-I. & Yeh, M.-K. Clinical development of liposome-based drugs: 
formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 7, 49–
60 (2012). 
74. Chen, C., Han, D., Cai, C. & Tang, X. An overview of liposome lyophilization 
and its future potential. J. Controlled Release 142, 299–311 (2010). 
75. Monopoli, M. P., Åberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas 
provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779–
786 (2012). 
76. Wolfram, J. et al. The nano-plasma interface: Implications of the protein 
corona. Colloids Surf. B Biointerfaces 124, 17–24 (2014). 
77. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects 
nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781 (2013). 
78. Casals, E., Pfaller, T., Duschl, A., Oostingh, G. J. & Puntes, V. Time Evolution 
of the Nanoparticle Protein Corona. ACS Nano 4, 3623–3632 (2010). 
79. Siegrist, S. et al. Preclinical hazard evaluation strategy for nanomedicines. 
Nanotoxicology 13, 73–99 (2019). 
80. Hamilton, F. & Swaine, J. An account of the fishes found in the river Ganges 
and its branches. 1–426 (Hurst, Robinson, and Co., 1822). 
doi:10.5962/bhl.title.59540. 
81. Spence, R., Gerlach, G., Lawrence, C. & Smith, C. The behaviour and ecology 
of the zebrafish, Danio rerio. Biol. Rev. Camb. Philos. Soc. (2008) 
doi:10.1111/j.1469-185X.2007.00030.x. 
128 |  
 
82. Engeszer, R. E., Patterson, L. B., Rao, A. A. & Parichy, D. M. Zebrafish in the 
wild: a review of natural history and new notes from the field. Zebrafish 4, 21–40 
(2007). 
83. Gerhard, G. S. et al. Life spans and senescent phenotypes in two strains of 
Zebrafish (Danio rerio). Exp. Gerontol. 37, 1055–1068 (2002). 
84. Howe, K. et al. The zebrafish reference genome sequence and its relationship 
to the human genome. Nature 496, 498–503 (2013). 
85. McCluskey, B. M. & Postlethwait, J. H. Phylogeny of Zebrafish, a “Model 
Species,” within Danio, a “Model Genus”. Mol. Biol. Evol. 32, 635–652 (2015). 
86. Meyers, J. R. Zebrafish: Development of a Vertebrate Model Organism. Curr. 
Protoc. Essent. Lab. Tech. 16, e19 (2018). 
87. Fang, F. Phylogenetic Analysis of the Asian Cyprinid Genus Danio (Teleostei, 
Cyprinidae). Copeia 2003, 714–728 (2003). 
88. Van Slyke, C. E., Bradford, Y. M., Westerfield, M. & Haendel, M. A. The 
zebrafish anatomy and stage ontologies: representing the anatomy and 
development of Danio rerio. J. Biomed. Semant. 5, 12 (2014). 
89. Rosenthal, G. G. & Ryan, M. J. Assortative preferences for stripes in danios. 
Anim. Behav. 70, 1063–1066 (2005). 
90. Parichy, D. M. Evolution of danio pigment pattern development. Heredity 97, 
200–210 (2006). 
91. White, R. M. et al. Transparent adult zebrafish as a tool for in vivo 
transplantation analysis. Cell Stem Cell 2, 183–189 (2008). 
92. Menke, A. L., Spitsbergen, J. M., Wolterbeek, A. P. M. & Woutersen, R. A. 
Normal Anatomy and Histology of the Adult Zebrafish. Toxicol. Pathol. 39, 759–
775 (2011). 
| 129   
 
93. Ellett, F. & Lieschke, G. J. Zebrafish as a model for vertebrate hematopoiesis. 
Curr. Opin. Pharmacol. 10, 563–570 (2010). 
94. Roberts, R. J. & Ellis, A. E. The Anatomy and Physiology of Teleosts. in Fish 
Pathology 17–61 (John Wiley & Sons, Ltd, 2012). 
doi:10.1002/9781118222942.ch2. 
95. Lieschke, G. J., Oates, A. C., Crowhurst, M. O., Ward, A. C. & Layton, J. E. 
Morphologic and functional characterization of granulocytes and macrophages in 
embryonic and adult zebrafish. Blood 98, 3087–3096 (2001). 
96. Bennett, C. M. et al. Myelopoiesis in the zebrafish, Danio rerio. Blood 98, 643–
651 (2001). 
97. Murtha, J. M., Qi, W. & Keller, E. T. Hematologic and serum biochemical 
values for zebrafish (Danio rerio). Comp. Med. 53, 37–41 (2003). 
98. Humphrey, J. D. Systemic Pathology of Fish: A Text and Atlas of Normal 
Tissues in Teleosts and their Response in Disease. J. Fish Dis. 30, 381–382 
(2007). 
99. Wulliman, M. F., Rupp, B. & Reichert, H. Neuroanatomy of the Zebrafish Brain: 
A Topological Atlas. (Birkhäuser Basel, 1996). doi:10.1007/978-3-0348-8979-7. 
100. Lieschke, G. J. & Currie, P. D. Animal models of human disease: zebrafish 
swim into view. Nat. Rev. Genet. 8, 353–367 (2007). 
101. Directive 2010/63/EU of the European Parliament and of the Council of 
22 September 2010 on the protection of animals used for scientific purposes Text 
with EEA relevance. 276 vol. OJ L (2010). 
102. Strähle, U. et al. Zebrafish embryos as an alternative to animal experiments—
A commentary on the definition of the onset of protected life stages in animal 
welfare regulations. Reprod. Toxicol. 33, 128–132 (2012). 
130 |  
 
103. Aleström, P. et al. Zebrafish: Housing and husbandry recommendations. Lab. 
Anim. 0023677219869037 (2019) doi:10.1177/0023677219869037. 
104. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. 
Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253–310 
(1995). 
105. Lajis, A. F. B. A Zebrafish Embryo as an Animal Model for the Treatment of 
Hyperpigmentation in Cosmetic Dermatology Medicine. Medicina (Mex.) 54, 35 
(2018). 
106. Creaser, C. W. The Technic of Handling the Zebra Fish (Brachydanio rerio) for 
the Production of Eggs Which Are Favorable for Embryological Research and Are 
Available at Any Specified Time Throughout the Year. Copeia 1934, 159–161 
(1934). 
107. Streisinger, G., Coale, F., Taggart, C., Walker, C. & Grunwald, D. J. Clonal 
origins of cells in the pigmented retina of the zebrafish eye. Dev. Biol. 131, 60–69 
(1989). 
108. Streisinger, G., Walker, C., Dower, N., Knauber, D. & Singer, F. Production of 
clones of homozygous diploid zebra fish ( Brachydanio rerio ). Nature 291, 293–
296 (1981). 
109. Chakrabarti, S., Streisinger, G., Singer, F. & Walker, C. FREQUENCY OF γ-
RAY INDUCED SPECIFIC LOCUS AND RECESSIVE LETHAL MUTATIONS IN 
MATURE GERM CELLS OF THE ZEBRAFISH, BRACHYDANIO RERIO. Genetics 
103, 109–123 (1983). 
110. Kimmel, C. B. Genetics and early development of zebrafish. Trends Genet. 5, 
283–288 (1989). 
111. Haffter, P. et al. Mutations affecting pigmentation and shape of the adult 
zebrafish. Dev. Genes Evol. 206, 260–276 (1996). 
| 131   
 
112. Davidson, A. E. et al. Efficient gene delivery and gene expression in zebrafish 
using the Sleeping Beauty transposon. Dev. Biol. 263, 191–202 (2003). 
113. Kwan, K. M. et al. The Tol2kit: A multisite gateway-based construction kit for 
Tol2 transposon transgenesis constructs. Dev. Dyn. 236, 3088–3099 (2007). 
114. Ellett, F., Pase, L., Hayman, J. W., Andrianopoulos, A. & Lieschke, G. J. 
mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish. 
Blood 117, e49–e56 (2011). 
115. Pliss, G. B. & Khudoley, V. V. Tumor Induction by Carcinogenic Agents in 
Aquarium Fish. JNCI J. Natl. Cancer Inst. 55, 129–136 (1975). 
116. de Soysa, T. Y. et al. Macondo crude oil from the Deepwater Horizon oil spill 
disrupts specific developmental processes during zebrafish embryogenesis. BMC 
Biol. 10, 40 (2012). 
117. Sieber, S. et al. Zebrafish as a predictive screening model to assess 
macrophage clearance of liposomes in vivo. Nanomedicine Nanotechnol. Biol. 
Med. 17, 82–93 (2019). 
118. Sieber, S. et al. Zebrafish as a preclinical in vivo screening model for 
nanomedicines. Adv. Drug Deliv. Rev. 151–152, 152–168 (2019). 
119. Strähle, U. & Grabher, C. The zebrafish embryo as a model for assessing off-
target drug effects. Dis. Model. Mech. 3, 689–692 (2010). 
120. Geisler, R., Köhler, A., Dickmeis, T. & Strähle, U. Archiving of zebrafish lines 
can reduce animal experiments in biomedical research. EMBO Rep. 18, 1–2 
(2017). 
121. BLV, B. für L. und V. 3R – Replace, Reduce, Refine – Tierversuche ersetzen, 
reduzieren, verbessern. 
https://www.blv.admin.ch/blv/de/home/tiere/tierversuche/3r-prinzipien.html. 
122. Al-Khalili, J. In retrospect: Book of Optics. Nature 518, 164–165 (2015). 
132 |  
 
123. Ockenga, W. A Brief History of Light Microscopy – From the Medieval Reading 
Stone to Super-Resolution. (2015). 
124. Robert Hooke. Micrographia, or some physiological descriptions of minute 
bodies made by magnifying glasses, with observations and inquiries thereupon. By 
R. Hooke. (Printed by JoMartyn, and JaAllestry, printers to the Royal Society, 
1665). 
125. Leeuwenhoek, A. V. More observations from Mr. Leewenhook, in a letter of 
Sept. 7. 1674. sent to the publisher. Philos. Trans. R. Soc. Lond. 9, 178–182 
(1674). 
126. History of Microscopes. Microscope.com 
https://www.microscope.com/education-center/microscopes-101/history-of-
microscopes. 
127. Kherlopian, A. R. et al. A review of imaging techniques for systems biology. 
BMC Syst. Biol. 2, 74 (2008). 
128. Thorn, K. A review of imaging techniques in scientific research/clinical 
diagnosis. MOJ Anat. Physiol. Volume 6, (2019). 
129. Thorn, K. A quick guide to light microscopy in cell biology. Mol. Biol. Cell 27, 
219–222 (2016). 
130. Masters, B. R. Fundamentals of Light Microscopy and Electronic Imaging, 
Second Edition. J. Biomed. Opt. 18, 029901 (2013). 
131. Day, R. N. & Davidson, M. W. The fluorescent protein palette: tools for cellular 
imaging. Chem. Soc. Rev. 38, 2887–2921 (2009). 
132. Reynolds, E. S. The use of lead citrate at high pH as an electron-opaque stain 
in electron microscopy. J. Cell Biol. 17, 208–212 (1963). 
| 133   
 
133. Gordon, R. E. Electron Microscopy: A Brief History and Review of Current 
Clinical Application. in Histopathology: Methods and Protocols (ed. Day, C. E.) 
119–135 (Springer, 2014). doi:10.1007/978-1-4939-1050-2_7. 
134. Tang, C. Y. & Yang, Z. Chapter 8 - Transmission Electron Microscopy (TEM). 
in Membrane Characterization (eds. Hilal, N., Ismail, A. F., Matsuura, T. & Oatley-
Radcliffe, D.) 145–159 (Elsevier, 2017). doi:10.1016/B978-0-444-63776-5.00008-
5. 
135. Mühlfeld, C. et al. Visualization and quantitative analysis of nanoparticles in 
the respiratory tract by transmission electron microscopy. Part. Fibre Toxicol. 4, 11 
(2007). 
136. Saghi, Z. & Midgley, P. A. Electron Tomography in the (S)TEM: From 
Nanoscale Morphological Analysis to 3D Atomic Imaging. Annu. Rev. Mater. Res. 
42, 59–79 (2012). 
137. Vernon-Parry, K. D. Scanning electron microscopy: an introduction. III-Vs Rev. 
13, 40–44 (2000). 
138. Murata, K. & Wolf, M. Cryo-electron microscopy for structural analysis of 
dynamic biological macromolecules. Biochim. Biophys. Acta BBA - Gen. Subj. 
1862, 324–334 (2018). 
139. Jonkman, J. & Brown, C. M. Any Way You Slice It—A Comparison of Confocal 
Microscopy Techniques. J. Biomol. Tech. JBT 26, 54–65 (2015). 
140. Jonkman, J., Brown, C. M. & Cole, R. W. Chapter 7 - Quantitative confocal 
microscopy: Beyond a pretty picture. in Methods in Cell Biology (eds. Waters, J. C. 
& Wittman, T.) vol. 123 113–134 (Academic Press, 2014). 
141. Flannery, B. P., Deckman, H. W., Roberge, W. G. & D’amico, K. L. Three-
Dimensional X-ray Microtomography. Science 237, 1439–1444 (1987). 
142. Sasov, A. Y. Microtomography. J. Microsc. 147, 169–178 (1987). 
134 |  
 
143. Ritman, E. L. Current Status of Developments and Applications of Micro-CT. 
Annu. Rev. Biomed. Eng. 13, 531–552 (2011). 
144. Landis, E. N. & Keane, D. T. X-ray microtomography. Mater. Charact. 61, 
1305–1316 (2010). 
145. Cengiz, I. F., Oliveira, J. M. & Reis, R. L. Micro-CT – a digital 3D 
microstructural voyage into scaffolds: a systematic review of the reported methods 
and results. Biomater. Res. 22, (2018). 
146. du Plessis, A., Yadroitsev, I., Yadroitsava, I. & Le Roux, S. G. X-Ray 
Microcomputed Tomography in Additive Manufacturing: A Review of the Current 
Technology and Applications. 3D Print. Addit. Manuf. 5, 227–247 (2018). 
147. Rahimabadi, P. S., Khodaei, M. & Koswattage, K. R. Review on applications 
of synchrotron-based X-ray techniques in materials characterization. X-Ray 
Spectrom. n/a,. 
148. What is a synchrotron? https://www.esrf.eu/about/synchrotron-
science/synchrotron. 
149. Swiss Light Source Accelerator Facility. Paul Scherrer Institut (PSI) 
https://www.psi.ch/en/sls/accelerator. 
150. What is synchrotron light? https://www.esrf.eu/about/synchrotron-
science/synchrotron-light. 
151. Beamlines. Paul Scherrer Institut (PSI) https://www.psi.ch/en/sls/beamlines. 
152. Li, Y.-F. et al. Synchrotron radiation techniques for nanotoxicology. 
Nanomedicine Nanotechnol. Biol. Med. 11, 1531–1549 (2015). 
153. Gao, Y. et al. Mapping technique for biodistribution of elements in a model 
organism, Caenorhabditis elegans, after exposure to copper nanoparticles with 
microbeam synchrotron radiation X-ray fluorescence. J. Anal. At. Spectrom. 23, 
1121–1124 (2008). 
| 135   
 
154. Ankley, G. T. et al. Adverse outcome pathways: A conceptual framework to 
support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 
730–741 (2010). 
155. Simkó, M., Nosske, D. & Kreyling, W. G. Metrics, Dose, and Dose Concept: 
The Need for a Proper Dose Concept in the Risk Assessment of Nanoparticles. Int. 
J. Environ. Res. Public. Health 11, 4026–4048 (2014). 
156. Sayes, C. M., Smith, P. A. & Ivanov, I. V. A framework for grouping 
nanoparticles based on their measurable characteristics. Int. J. Nanomedicine 8, 
45–56 (2013). 
157. Lynch, I., Weiss, C. & Valsami-Jones, E. A strategy for grouping of 
nanomaterials based on key physico-chemical descriptors as a basis for safer-by-
design NMs. Nano Today 9, 266–270 (2014). 
158. Lamon, L., Aschberger, K., Asturiol, D., Richarz, A. & Worth, A. Grouping of 
nanomaterials to read-across hazard endpoints: a review. Nanotoxicology 13, 
100–118 (2019). 
159. Kirk, R. G. W. Recovering The Principles of Humane Experimental Technique. 
Sci. Technol. Hum. Values 43, 622–648 (2018). 
160. Sailor, M. J. & Park, J.-H. Hybrid Nanoparticles for Detection and Treatment 
of Cancer. Adv. Mater. Deerfield Beach Fla 24, 3779–3802 (2012). 
161. Bohara, R. A. & Thorat, N. D. Hybrid Nanostructures for Cancer Theranostics. 
(Elsevier, 2018). 
162. Kim, D. K., Mikhaylova, M., Zhang, Y. & Muhammed, M. Protective Coating of 
Superparamagnetic Iron Oxide Nanoparticles. Chem. Mater. 15, 1617–1627 
(2003). 
136 |  
 
163. Arias, L. S. et al. Iron Oxide Nanoparticles for Biomedical Applications: A 
Perspective on Synthesis, Drugs, Antimicrobial Activity, and Toxicity. Antibiotics 7, 
(2018). 
164. Usov, N. A. Iron Oxide Nanoparticles for Magnetic Hyperthermia. SPIN 09, 
1940001 (2019). 
165. Ferreira, R. V. et al. Thermosensitive gemcitabine-magnetoliposomes for 
combined hyperthermia and chemotherapy. Nanotechnology 27, 085105 (2016). 
166. Bietenbeck, M., Florian, A., Faber, C., Sechtem, U. & Yilmaz, A. Remote 
magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and 
therapeutic drug delivery: where are we now? Int J Nanomedicine 11, 3191–3203 
(2016). 
167. Mourdikoudis, S., Pallares, R. M. & Thanh, N. T. K. Characterization 
techniques for nanoparticles: comparison and complementarity upon studying 
nanoparticle properties. Nanoscale 10, 12871–12934 (2018). 
168. Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy 
for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 
99, 28–51 (2016). 
169. Li, Y., Kröger, M. & Liu, W. K. Shape effect in cellular uptake of PEGylated 
nanoparticles: comparison between sphere, rod, cube and disk. Nanoscale 7, 
16631–16646 (2015). 
170. Lee, K. J., Nallathamby, P. D., Browning, L. M., Osgood, C. J. & Xu, X.-H. N. 
In Vivo Imaging of Transport and Biocompatibility of Single Silver Nanoparticles in 
Early Development of Zebrafish Embryos. ACS Nano 1, 133–143 (2007). 
171. Chakraborty, C., Sharma, A. R., Sharma, G. & Lee, S.-S. Zebrafish: A 
complete animal model to enumerate the nanoparticle toxicity. J. 
Nanobiotechnology 14, 65 (2016). 
| 137   
 
172. Arms, L. et al. Advantages and Limitations of Current Techniques for Analyzing 
the Biodistribution of Nanoparticles. Front. Pharmacol. 9, (2018). 
173. du Plessis, A., Broeckhoven, C., Guelpa, A. & le Roux, S. G. Laboratory x-ray 
micro-computed tomography: a user guideline for biological samples. GigaScience 
6, 1–11 (2017). 
174. Bharti, A. & Goyal, N. Fundamental of Synchrotron Radiations. Synchrotron 
Radiat. - Useful Interes. Appl. (2019) doi:10.5772/intechopen.82202. 
175. Bagnell, C. R., Zernike, J. F. & Zernike, J. F. Chapter 10 Phase Contrast Types 




176. Paganin, D., Mayo, S. C., Gureyev, T. E., Miller, P. R. & Wilkins, S. W. 
Simultaneous phase and amplitude extraction from a single defocused image of a 
homogeneous object. J. Microsc. 206, 33–40 (2002). 
177. Gureyev, T. E. et al. Investigation of the imaging quality of synchrotron-based 
phase-contrast mammographic tomography. J. Phys. Appl. Phys. 47, 365401 
(2014). 
178. Unterweger, H. et al. Development and characterization of magnetic iron oxide 
nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery. 
International Journal of Nanomedicine https://www.dovepress.com/development-
and-characterization-of-magnetic-iron-oxide-nanoparticles--peer-reviewed-
fulltext-article-IJN (2014) doi:10.2147/IJN.S63433. 
179. Unterweger, H. et al. Non-immunogenic dextran-coated superparamagnetic 
iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic 
resonance imaging. International Journal of Nanomedicine 





180. Zaloga, J. et al. Pharmaceutical formulation of HSA hybrid coated iron oxide 
nanoparticles for magnetic drug targeting. Eur. J. Pharm. Biopharm. 101, 152–162 
(2016). 
181. Chiu, C.-Y., Chung, T.-W., Chen, S.-Y. & Ma, Y.-H. Effects of PEGylation on 
capture of dextran-coated magnetic nanoparticles in microcirculation. Int. J. 
Nanomedicine 14, 4767–4780 (2019). 
182. Schlenvoigt, H.-P. et al. A compact synchrotron radiation source driven by a 
laser-plasma wakefield accelerator. Nat. Phys. 4, 130–133 (2008). 
183. Hu, G. et al. Nanoparticles Targeting Macrophages as Potential Clinical 
Therapeutic Agents Against Cancer and Inflammation. Front. Immunol. 10, (2019). 
184. Ahmed, D. et al. Rotational manipulation of single cells and organisms using 
acoustic waves. Nat. Commun. 7, 1–11 (2016). 
185. Ahmed, D. et al. Selectively manipulable acoustic-powered microswimmers. 
Sci. Rep. 5, 1–8 (2015). 
186. Ahmed, D. et al. Artificial Swimmers Propelled by Acoustically Activated 
Flagella. Nano Lett. 16, 4968–4974 (2016). 
187. Dolev, S. & Narayanan, R. Towards radio transceiving in-vivo nano-robots. SN 
Appl. Sci. 1, 969 (2019). 
188. Soto, F. & Chrostowski, R. Frontiers of Medical Micro/Nanorobotics: in vivo 
Applications and Commercialization Perspectives Toward Clinical Uses. Front. 
Bioeng. Biotechnol. 6, (2018). 
 






I want to express my deepest gratitude to Prof. Dr. Jörg Huwyler for giving me the 
opportunity to start and finish my PhD thesis in his laboratories of Pharmaceutical 
Technology. I had a great time, learned a lot, and made a huge amount of 
experience during my work. Jörg was a great mentor, supervisor and motivator. 
I am very grateful for this period of time in my life. Thank you, Jörg! 
 
 
Also, I want to thank Prof. Dr. Alex Odermatt, Head of Molecular & Systems 
Toxicology group, for being my second supervisor. We know each other since my 
time during my Master’s thesis in Toxicology at the University of Basel where he 
was my academic supervisor. I am happy to finish now another huge part of my 
career and that you are part of it again. 
 
 
Special thanks goes out to Prof. Dr. Gert Fricker, Director and Dean of Studies, 
Institute of Pharmacy and Molecular Biotechnology, Group of Pharmaceutical 




I also want to thank Prof. Dr. Martin Wilks, Director of Swiss Centre for Applied 
Human Toxicology (SCAHT) in Basel for being my chairperson during my Ph.D. 
exam.  
  
140 |  
 
Besides of that, I want to thank Susanne Schenk for taking care of our lab. It was 
always perfectly organized and tidy for which I am very grateful. Further thanks 
goes out to the whole Pharmaceutical Technology group consisting of Denise Ruoff, 
Darryl Borland, Stefan Winzap, Maxim Puchkov, Pascal Detampel, Tomaz Einfalt, 
Stefan Siegrist, Sandro Sieber, Jana Kovac, Christina Häuser, Ilona Vollrath, Anna 
Pratsinis, Philip Grossen, Dominik Witzigmann, Jonas Buck, Claudio Luca Alter, Jan 
Stephan Bolten, Patrick Hauswirth, Andreas Shittny, Maryam Farzan, Tim 
Dreckmann, Nina Ariane Schmidt, Joachim Schuster, Viktoria Schreiner, Leonie 
Wagner-Hattler, Gaby Québatte, Klara Kiene, and Daniel Kullmann.  
 
 
Also, many thanks to my collaboration partners from EMPA (Dr. Peter Wick), 
SCAHT (Prof. Dr. Martin Wilks, Dr. Lothar Aicher, Dr. Jenny Sandström), HEPIA 
Genf (Prof. Dr. Luc Stoppini, Prof. Dr. Adrien Roux), Biomaterials Science Center 
(Prof. Dr. Bert Müller, Dr. Georg Schulz, Dr. Peter Thalmann, Dr. Cristos Bikis, Dr. 
Griffin Rodgers), PSI (Dr. Christian Schlepütz), and of course ETH Zürich (Prof. Dr. 




Finally, I want to thank my parents and my little brother.  
You always supported me and without you, I would not be here today.  
I can be happy that you raised me with great values and showed me what is 
important in life.      
 
